Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00170469 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed
A Phase 2 study of Bacillus Anthracis (Anthrax), sponsored by PharmAthene UK Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 226
- Enrollment target
- 16
- Study locations
NCT00170469 is a Phase 2 study of Bacillus Anthracis (Anthrax) that has completed, run by PharmAthene UK Limited. The registered enrollment target is 226 participants. The trial reports 16 study locations across 10 states.
The verdict
NCT00170469, a Phase 2 study of Bacillus Anthracis (Anthrax), has completed, sponsored by PharmAthene UK Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 226 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a dose ranging study comparing different vaccine schedules of rPA vaccine, for Anthrax, to the licensed dose of AVA, another Anthrax vaccine. Safety and the capability to induce an immune response will be evaluated.
Conditions Studied
Interventions
- BIOLOGICAL AVA
- BIOLOGICAL rPA vaccine containing alhydrogel
Study Locations (16)
Florida
- Florida Medical Research Institute - Gainesville
- Accelovance - Melbourne
- Miami Research Associates - South Miami
Alabama
- Greater Huntsville Family Practice, PC - Huntsville
- Discovery Alliance, Inc. - Mobile
Oklahoma
- Accelovance - Oklahoma City
- Lynn Health Science Institute - Oklahoma City
Texas
- PharamTex Research, Inc. - Amarillo
- Accelovance - Houston
Virginia
- Metropolitan Research - Fairfax
- Carilion Medical Associates - Galax
California
- Accelovance - San Diego
District of Columbia
- Accelovance - Washington D.C.
Illinois
- Accelovance - Orland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00170469
The ClinicalTrials.gov registry entry for NCT00170469 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmAthene UK Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bacillus Anthracis (Anthrax) appearing as the primary indexed condition, and to 2 interventions - of which AVA is the first listed.
NCT00170469 reports 16 study locations spanning 10 distinct geographic areas - top geographies include Florida, Alabama, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT00170469 about?
NCT00170469 is a clinical study titled "Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed". This is a dose ranging study comparing different vaccine schedules of rPA vaccine, for Anthrax, to the licensed dose of AVA, another Anthrax vaccine. Safety and the capability to induce an immune response will be evaluated.
What is the current status of trial NCT00170469?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2005-03. Estimated completion is 2007-02.
What conditions does trial NCT00170469 study?
This clinical trial studies the following conditions: Bacillus Anthracis (Anthrax).
What interventions are being tested in trial NCT00170469?
The interventions under investigation include: AVA (BIOLOGICAL), rPA vaccine containing alhydrogel (BIOLOGICAL).
Who is sponsoring clinical trial NCT00170469?
This trial is sponsored by PharmAthene UK Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00170469 being conducted?
This trial has 16 study locations across Alabama, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.